Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1 on the page; there are no visible changes to the study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No user-visible changes to study details or page content.SummaryDifference0.1%

- Check28 days agoChange DetectedAdded a Show glossary option and the label 'Last Update Submitted that Met QC Criteria' with a revision note 'Revision: v3.4.0'. Removed 'No FEAR Act data' and updated capitalization of related labels.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page revision history was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a Locations section with Virginia and its details; removed the HHS Vulnerability Disclosure and Virginia Locations, and updated to Revision: v3.3.3.SummaryDifference0.2%

- Check71 days agoChange DetectedThe page now shows 'Results Submitted' instead of 'No Results Posted', indicating that trial results have been submitted.SummaryDifference0.1%

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.